Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Epigenetic abnormality is a hallmark of acute myeloid leukemia (AML), and aberrant 5-hydroxymethylcytosine (5hmC) levels are commonly observed in AML patients. As epigenetic subgroups of AML correlate with different clinical outcomes, we investigated whether plasma cell-free DNA (cfDNA) 5hmC could categorize AML patients into subtypes. We profiled the genome-wide landscape of 5hmC in plasma cfDNA from 54 AML patients. Using an unbiased clustering approach, we found that 5hmC levels in genomic regions with a histone mark H3K4me3 classified AML samples into three distinct clusters that were significantly associated with leukemia burden and survival. Cluster 3 showed the highest leukemia burden, the shortest overall survival of patients, and the lowest 5hmC levels in the TET2 promoter. 5hmC levels in the TET2 promoter could represent TET2 activity resulting from mutations in DNA demethylation genes and other factors. The novel genes and key signaling pathways associated with aberrant 5hmC patterns could add to our understanding of DNA hydroxymethylation and highlight the potential therapeutic targets in AML. Our results identify a novel 5hmC-based AML classification system and further underscore cfDNA 5hmC as a highly sensitive marker for AML.

Original languageEnglish (US)
Article number1180
JournalGenes
Volume14
Issue number6
DOIs
StatePublished - May 28 2023

Keywords

  • 5-hydroxymethylcytosine
  • acute myeloid leukemia
  • cell-free DNA
  • classification
  • Proto-Oncogene Proteins/genetics
  • Humans
  • 5-Methylcytosine/metabolism
  • Leukemia, Myeloid, Acute/genetics

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Fingerprint

Dive into the research topics of 'Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine'. Together they form a unique fingerprint.

Cite this